Legal Proceedings and Contingencies Narrative (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended				6 Months Ended					1 Months Ended		3 Months Ended	6 Months Ended	12 Months Ended	1 Months Ended	6 Months Ended	1 Months Ended	6 Months Ended		6 Months Ended			12 Months Ended	1 Months Ended
	Jul. 03, 2011		Jul. 04, 2010		Jul. 03, 2011		Jul. 04, 2010		Jul. 03, 2011 Hormone Replacement Therapy [Member]	Dec. 31, 2005 Pending or Threatened Litigation [Member] March 2005 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Mar. 31, 2005 Pending or Threatened Litigation [Member] March 2005 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Sep. 26, 2004 Pending or Threatened Litigation [Member] March 2005 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Jul. 03, 2011 Pending or Threatened Litigation [Member] Court settlement rejection and Pfizer motion to appeal [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Dec. 31, 2010 Pending or Threatened Litigation [Member] Court settlement rejection and Pfizer motion to appeal [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Mar. 31, 2011 Pending or Threatened Litigation [Member] March 2011 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Jul. 03, 2011 Pending or Threatened Litigation [Member] March 2011 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Aug. 31, 2004 Pending or Threatened Litigation [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Jul. 03, 2011 Pending or Threatened Litigation [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Dec. 31, 2010 Pending or Threatened Litigation [Member] American Optical Corp subsidiary of Warner-Lambert [Member]	Jul. 03, 2011 Pending or Threatened Litigation [Member] Pfizer - Neurontin Product [Member]	Jan. 31, 2011 Pending or Threatened Litigation [Member] Pfizer - Neurontin Product [Member]	Nov. 30, 2010 Pending or Threatened Litigation [Member] Pfizer - Neurontin Product [Member]	Dec. 31, 2008 Pending or Threatened Litigation [Member] Pharmacia - Average Wholesale Price Litigation [Member]	Jul. 31, 2009 Pending or Threatened Litigation [Member] IREF -Trade Secrets Action [Member]	Dec. 31, 2008 Pending or Threatened Litigation [Member] IREF -Trade Secrets Action [Member]
Product Liability Contingency [Line Items]
Product litigation charge, pre-tax	$ (14)	[1]	$ 37	[1]	$ 487	[1]	$ 174	[1]				$ 369		$ 1,300
Product litigation charge, after-tax												229		800
Notice of appeal and related motion													October 2010
Number of Ad Hoc Committee claimants agreeing to the company's proposed settlement offer															40,000
Percentage of claimants' vote received on the proposed bankruptcy reorganization of the defendant entity											75.00%
Number of defendants																							11
Percentage of claimants that agreed to 2004 proposed settlement											80.00%
Gross settlement amount offered											430												125
Claims payment amount for qualified claimants, first or only payment										215						500
Claims payment amount for qualified claimants, second payment																300
Claims installment, payment terms																Following the earlier of the effective date of a revised plan of reorganization and April 6, 2013
Agreed-upon payment amount of plaintiff's legal fees and expenses																19
Agreed upon amount of assets (cash and non-cash) to be contributed to a special purpose trust created to pay claimants, if Quigley's proposed reorganization plan is approved by the court																550
Insurance settlement, gross recovery																	405
Insurance settlement collection period, in years																		10
Number of claims seeking damages																			88,000
Litigation settlement expense									250
Cumulative product liability charges in prior years									300
Estimated minimum cost to resolve outstanding actions									280
Cumulative percentage of actions settled									41.00%
Damages awarded by the court																					47.4	65.4			38.7
Treble damages amount awarded, under appeal																					$ 142.2
Actions being taken by Pfizer																				In August 2011, Pfizer appealed the District Court's judgment to the US Court of Appeals				The court has granted Pfizer's motion for a new trial and vacated the jury verdict

[1] In the first six months of 2011, primarily relates to charges for hormone-replacement therapy litigation (see Note 14. Legal Proceedings and Contingencies).